Beta-blocker Administration for Cardiomyocyte Division
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
Heart failure is a common long-term complication in patients with congenital heart disease
(CHD). Medical treatments to promote regeneration of new healthy heart muscle cells have the
potential to provide new heart failure treatments for these patients. The development of such
therapies is limited by the poor understanding of the ways in which heart muscles grow after
birth. Investigators have learned that humans without heart disease generate new heart
muscles cells up to the age of 20 years old and that this is decreased in patients with
congenital heart disease like Tetralogy of Fallot. Investigators are trying to determine if
treatment with a medicine called Propranolol can increase heart muscle cell proliferation
and, with that, normalize heart growth. Investigators will examine discarded heart muscle
tissue that is obtained during surgery for the presence of new heart muscle cells.
Propranolol is approved by the Food and Drug Administration (FDA) to treat a certain kind of
benign tumor in infants (hemangioma), but it is not currently approved by the FDA to increase
heart muscle growth.